Literature DB >> 29571851

In a stroke cohort with incident hypertension; are more women than men likely to be excluded from recombinant tissue-type Plasminogen Activator (rtPA)?

Jordan Gainey1, Leanne Brechtel1, Sarah Konklin2, Lee Madeline3, Ervin Lowther3, Brice Blum1, Thomas I Nathaniel4.   

Abstract

BACKGROUND: The treatment outcomes in the use of rt-PA have been reported. Some studies reported worse outcome in women than men, while others presented opposing data. Using data from a hospital-based stroke registry, we investigated evidence of gender difference and determined exclusion criteria in a stroke population with incidence of hypertension.
METHOD: In a stroke population of women and men with incident of hypertension from a stroke registry, demographics and clinical factors were compared. Univariate analysis was used to determine gender differences, while multivariable models adjusted for demographic and clinical variables.
RESULTS: Among the 669 stroke patients with incident of hypertension that were excluded from rt-PA treatment, 362 were female and 307 were male. Female patients with increasing age (OR = 0.956-0.984, P < 0.001), diabetes mellitus (OR = 0.095-0.559, P = 0.001), higher NIH stroke scale score (OR = 1.019-1.090, P = 0.002), previous stroke (OR = 0.337-0.850, P = 0.008), diabetes medication (OR = 1.200-7.724, P = 0.019), and INR (OR = 0.033-0.597, P = 0.008) are more likely to be excluded. Male patients with a history of a previous stroke (OR = 0.265-0.704, P = 0.001), risk of mortality (OR = 0.803-0.950, P = 0.002), higher NIH stroke scale score(OR = 1.101-1.276, P < 0.001), cholesterol reducing medication (OR = 1.191-2.910, P = 0.006), weakness at presentation(OR = 1.207-4.421, P = 0.011), and INR (OR = 0.016-0.243, P < 0.001) are more likely to be excluded.
CONCLUSION: Women have a worse outcome than men in an untreated acute ischemic stroke population, but when treated, women have a better treatment outcome compared to men. In a hypertensive stroke population, the clinical variables for the exclusion criteria for women and men are significantly different, even after adjustment for confounding variables.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Activator (rtPA); Acute ischemic stroke; Gender; Recombinant tissue-type plasminogen

Mesh:

Substances:

Year:  2018        PMID: 29571851     DOI: 10.1016/j.jns.2018.02.016

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  11 in total

1.  Gender and thrombolysis therapy in acute ischemic stroke patients with incidence of obesity.

Authors:  Brice Blum; Alexandria Penwell; Leah Wormack; Brittany Walker; Shyyon Lari; Thomas I Nathaniel
Journal:  Neurol Sci       Date:  2019-05-02       Impact factor: 3.307

2.  Gender differences in comorbidities and risk factors in ischemic stroke patients with a history of atrial fibrillation.

Authors:  Chase Rathfoot; Camron Edrissi; Carolyn Breauna Sanders; Krista Knisely; Nicolas Poupore; Thomas Nathaniel
Journal:  BMC Neurol       Date:  2021-05-25       Impact factor: 2.474

3.  The Association Between an Antecedent of Transient Ischemic Attack Prior to Onset of Stroke and Functional Ambulatory Outcome.

Authors:  Nicolas Poupore; Dan Strat; Tristan Mackey; Thomas I Nathaniel
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

4.  Stroke and dyslipidemia: clinical risk factors in the telestroke versus non-telestroke.

Authors:  Jordan Gainey; Brice Blum; Bekah Bowie; Keiko Cooley; Lee Madeline; Ervin Lowther Ervin; Thomas I Nathaniel
Journal:  Lipids Health Dis       Date:  2018-09-27       Impact factor: 3.876

5.  Gender and thrombolysis therapy in stroke patients with incidence of dyslipidemia.

Authors:  Brice Blum; Leah Wormack; Mason Holtel; Alexandria Penwell; Shyyon Lari; Brittany Walker; Thomas I Nathaniel
Journal:  BMC Womens Health       Date:  2019-01-16       Impact factor: 2.809

6.  In acute ischemic stroke patients with smoking incidence, are more women than men more likely to be included or excluded from thrombolysis therapy?

Authors:  Oluyemi R Rotimi; Iretioluwa F Ajani; Alexandria Penwell; Shyyon Lari; Brittany Walker; Thomas I Nathaniel
Journal:  Womens Health (Lond)       Date:  2020 Jan-Dec

7.  Ischemic stroke with a preceding Trans ischemic attack (TIA) less than 24 hours and thrombolytic therapy.

Authors:  Nicolas Poupore; Dan Strat; Tristan Mackey; Ashley Snell; Thomas Nathaniel
Journal:  BMC Neurol       Date:  2020-05-19       Impact factor: 2.474

8.  Effect of antihypertensive medications on thrombolysis therapy and outcomes in acute ischemic stroke patients.

Authors:  Tyler Fleming; Brice Blum; Benjamin Averkamp; James Sullivan; Thomas Nathaniel
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-01-23       Impact factor: 3.738

9.  Obstructive sleep apnea and stroke severity: Impact of clinical risk factors.

Authors:  Carolyn Breauna Sanders; Krista Knisely; Camron Edrissi; Chase Rathfoot; Nicolas Poupore; Leah Wormack; Thomas Nathaniel
Journal:  Brain Circ       Date:  2021-05-29

10.  Cholesterol reducer and thrombolytic therapy in acute ischemic stroke patients.

Authors:  Nicolas Poupore; Dan Strat; Tristan Mackey; Katherine Brown; Ashley Snell; Thomas I Nathaniel
Journal:  Lipids Health Dis       Date:  2020-05-06       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.